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Dear Editor, 
We thank Gachabayov et al for their thoughts and appreciation of our recently published 
International Expert Consensus Guidance on TaTME [1], and the opportunity to clarify any 
misunderstandings regarding its purpose and methodology.  Firstly, the panellists consisted of 56 
internationally known and respected surgeons, experienced in managing rectal cancer not only 
by TaTME but also by the abdominal approaches.  They have performed over 50 TaTME cases 
each, taught on cadaveric courses, and published literature on the technique.  They were also 
identified and recommended by their national colorectal surgical societies.  Given that the aim of 
the consensus was to formulate guidance specifically on the safe implementation and application 
of TaTME, rather than the management of rectal cancer as a whole, it is very reasonable for the 
panel to be composed of practicing surgeons experienced in TaTME.  The number of panellists 
allowed us to bring together the worldwide experience of the technique, with representatives 
from each of the 14 international societies who also recognised and endorsed the importance of 
this project.  Five rounds of Delphi were required to reach agreement on the statements over 
three years, suggesting that conformity bias was unlikely as each surgeon clearly expressed their 
opinion leading to many hours of discussion.  The authors quote that 16% of the panellists have a 
conflict of interest.  As stated on the consensus article and on the contrary to another misleading 
consideration, none of the participants have any direct conflict of interest with regards to the 
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participants.  It is not unusual, and in the current era of advancing technical innovation, for 
specialist senior surgeons to consult and provide direction for these companies.    
Secondly, the methodology used consisted of an adapted Delphi method and focus group 
discussion approach, guided by an expert in guidelines methodology.  Consensus was considered 
achieved when agreement level of >80% was reached.  The authors reference a perspective on 
the Delphi process by Waggoner et al [2] in which the opinion of the three authors was to only 
include a panel size of 6 – 11 members, based on a few studies and “the lack of current research” 
[2].  This is in contrast to an extensive set of experiments conducted at the RAND corporation 
which clearly showed a positive correlation between increasing number of participants with 
accuracy and reliability of the responses [3].  The size of the panel in most Delphi studies is 
incredibly variable [2], and often reflects the research question and underlying purpose of 
conducting the Delphi process which may well lead to varying numbers of participants.      
The guidance group acknowledged that at the present time there is no level 1 evidence on 
TaTME.  However, published evidence is accumulating rapidly and, hence we proposed the new 
concept of “dynamic guidance”, whereby the guidance could be updated as more evidence 
becomes available.  Randomised controlled trials such as COLOR III [4] and ETAP-GRECCAR11 [5] 
have started patient recruitment but results will not be available for some time. Given the 
dynamic character of the statements, we also strongly advocated all societies to publish these 
guidance statements online for review and critical appraisal of their respective membership. Peer 
review by the wider colorectal community will allow further adaptation and improvement of the 
current statements.
We agree that “Clinical expertise in the era of evidence-based medicine and patient choice 
should be integrated with evidence, patients’ preferences, and clinical circumstances” [6].  
However, in the context of surgical innovation this is not so straight forward as a technique (and 
the surgeon’s skill in performing it) may still be evolving and its true benefits and risks not fully 
known yet.  
TaTME is currently in the early part of the assessment phase of the IDEAL framework for surgical 
innovation [7].  Despite following the IDEAL recommendations and steps closely, especially 
during the early development of the technique [8], the explorative phase saw a huge surge in 
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to adequate training and provision of experienced proctors.  Unsurprisingly, problems soon arose 
with concerns regarding urethral injuries [8], CO2 embolus [10] and more recently local 
recurrence [11,12].  It is exactly during these times of widespread discussion and concern about a 
technique that a consensus is needed.  Although the panellists in this consensus may be viewed 
as being “in favour of TaTME” simply because they perform the technique, the guidance 
produced actually calls for caution and sets more preconditions and direction for surgeons 
considering adopting TaTME.  By having personally faced the challenges that TaTME can bring, 
the panellists acknowledge that certain standards and pre-requisites are necessary in order to 
safely implement the technique.  Pre-requisites, such as a minimum annual volume of TME cases, 
obtaining appropriate training and acquiring advanced surgical skills, are not achievable in every 
colorectal unit; thus limiting the adoption of TaTME.  Furthermore, by setting these standards 
through the consensus process, self-licensing is more likely to be prevented.   
Finally, we feel that the statement “the concept of expert canters is outdated” is incorrect.  
Expert centres for novel and challenging techniques are vitally important for their safe 
introduction.  Parallels have already been seen with minimally invasive oesophagectomy [13] and 
endovascular aortic aneurysm repair [14].  The definition of ‘expert centre’ in our consensus 
contained three components: 1) Centre specifications; 2) Surgeon expertise; 3) Centre 
performance/outcomes.  The latter two categories actually achieved agreement levels of 97.9% 
and 91.7%, respectively.  Only ‘centre specifications’ obtained 62.5% agreement despite lengthy 
discussions and a further Delphi round.  The discussion points regarding this component 
highlighted the diversity in surgical practice and resource availability around the globe.  However, 
the panellists agreed that complex high-risk cases should not be performed in low volume units 
sporadically by inexperienced surgeons.  Regular exercise of an activity or skill is the way to 
become proficient in it, hence the importance of securing a high case volume in a well-resourced 
department.
In conclusion, TaTME captured the colorectal community’s attention, due to perceived 
advantages, and enthusiasm has led to widespread uncontrolled adoption.  This occurred despite 
the lack of high-level evidence of its equivalence to conventional TME approaches.  The 
International Expert Consensus Guidance aims to promote a more cautious and considered 
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collaboration, sharing of experiences, high-quality research and regular review of available 
evidence, surgical innovation can continue to evolve and allow us to provide better patient care.
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